congestive heart failure chf epidemiology forecast insight
DelveInsight’s ‘Congestive Heart Failure (CHF)—Epidemiology Forecast–2034’ report delivers an in-depth understanding of the HF, historical and forecasted epidemiology as well as the HF trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Congestive Heart Failure (CHF) Disease Understanding
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes the shortness of breath and fatigue (tiredness) and the right-side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.
The body depends on the heart to pump and deliver oxygen and nutrient-rich blood to every cell. When the cells are nourished accurately, the body gains the ability to work normally. With HF, the weakened heart is not able to supply nutrients to the cells with enough blood which results in fatigue and shortness of breath and some people coughing (American Heart Association, n.d.)
HF is triggered by structural and functional limitations in the myocardium resulting in damage of ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves or large vessels alone or in the combination. Some of the major pathogenic mechanisms leading to HF are excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodeling, extreme or inadequate production of the extracellular matrix, enhanced apoptosis and genetic mutations.
Congestive Heart Failure (CHF) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, Type-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, Diagnosed Prevalent cases of HF associated with comorbidities scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2021 to 2034.
Key Findings
- Total Diagnosed Prevalent Cases of Heart Failure (HF) in the 7MM was found to be 12,602,028 in 2020, which is expected to grow during the study period (2021-2034).
- Among 7MM, the United States has the highest diagnosed prevalent population of HF, i.e., 5,163,119 cases in 2020, which is 40.97% of the total diagnosed cases of HF in the 7MM.
- In EU-5, Germany has the highest number of diagnosed cases, i.e., 2,216,497 followed by Spain with 1,283,827 cases and Italy with 1,164,031 cases. While, UK has the least number of cases with 728,547 in 2020.
- There are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others. Amongst them in the US, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease, and Dilated cardiomyopathy.
- Age-specific diagnosed prevalent cases are seen maximum in the age group of 75–84 (1,607,918) and lowest in <44 (155,410) in 2020, this is due to the progressive aging of the population as well as improved and better survival after cardiac insults, such as myocardial infarction, especially in developed countries.
- In 2020, the estimated cases of HFpEF (HFmEF) and HFrEF in the US were 3,097,871 and 2,065,247 which is expected to increase by 2034.
- In 2020, New York Heart Association (NYHA) Classification is comprised of class I (No symptoms and no limitation in ordinary physical activity), class II (Mild symptoms and slight limitation during ordinary activity), class III (Marked limitation in activity due to symptoms, even during less than ordinary activity), and class IV (Severe limitations) cases which were estimated to be 2,633,191, 1,512,794, 516,312, and 516,312 cases, in the US.
- In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.
- Heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age. According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females, in the US.
Country Wise- Congestive Heart Failure Epidemiology
The epidemiology segment also provides the congestive heart failure epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Scope of the Report
- The report covers the descriptive overview of HF, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of HF.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, Type-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, and Diagnosed Prevalent cases of HF associated with comorbidities.
Report Highlights
- 10-Year Forecast of HF
- 7MM Coverage
- Total Prevalent Cases of HF
- Diagnosed Prevalent Cases of HF
- Type-specific diagnosed prevalent cases of HF
- Gender-specific Cases of HF
- Age-specific Cases of HF
- NYHA Class-specific diagnosed prevalence of HF
- Diagnosed prevalent cases of Heart Failure with Ejection Fraction
- Diagnosed Prevalent cases of Heart Failure associated with comorbidities
Key Questions Answered
- What are the disease risk, and burden of HF ?
- What is the historical HF patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of HF at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HF ?
- Out of the above-mentioned countries, which country would have the highest prevalent population of HF during the forecast period (2025-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?
Reasons to buy
The HF report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM HF epidemiology forecast.
- The HF epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The HF epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
